Top Healthcare and Biotech Focused Hedge Funds Surge; Oversee $70 Billion in Equity Assets
|April 20th, 2014||
|The most recent Top 50 Healthcare, Pharmaceutical and Biotechnology Focused Hedge Fund list has been released, revealing that the top hedge funds now manage $70 billion in U.S. equity assets. Larry Robbins’ Glenview Capital Management has retained the top spot, once again, with $13.2 billion in equity assets under management. Glenview Capital’s sector favorites include Thermo Fisher Scientific (TMO), HCA Holdings Inc (HCA) and Health Management Associates (HMA). Over the last quarter, Glenview Capital notably increased its bets on Tenet Healthcare (THC) and Aetna Inc (AET).|
Other top investors that lead the Top Healthcare, Pharma and Biotech Hedge Fund List include #2 OrbiMed Advisors, #3 Baker Bros. Advisors LLC, and #4 Partner Fund Management. The largest investments for OrbiMed Advisors, which is run by industry stalwart Samuel Isaly, include Gilead Sciences Inc (GILD), Biogen Idec Inc (BIIB) and Bristol-Myers Squibb (BMY). Notably, Isaly’s firm entered and bought up large stakes in Relypsa Inc (RLYP), Perrigo Co (PRGO) and Acceleron Pharma (XLRN) over the quarter, while also increasing its stakes in Abbvie Inc (ABBV) and Celgene Corp (CELG).
Baker Bros. Advisors’ top positions include Pharmacyclics Inc (PCYC), Seattle Genetics (SGEN) and Incyte Corp (INCY), while Partner Fund Management’s top industry picks include Gilead Sciences Inc (GILD), Bristol-Myers Squibb (BMY) and Actavis Inc (ACT).
Ranking Methodology: The Top Healthcare, Pharmaceutical and Biotechnology Hedge Fund rankings are compiled on a quarterly basis using hedge fund firms’ overall U.S. equity assets under management. The list includes the top hedge funds that have more than 35% of their U.S. equity assets invested in U.S. listed Healthcare, Pharma & Biotech companies. To view the Top Healthcare, Pharma & Biotech Hedge Fund list in its entirety, please visit HedgeTracker’s Hedge Fund Portal.
For Detailed Investor Profiles on these Investors, click below: